Cited by 317Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.

Fyn inhibition rescues established memory and synapse loss in Alzheimer mice

Open access

Kaufman, Adam C., Salazar, Santiago V., Haas, Laura T., Yang, Jinhee, Kostylev, Mikhail A., Jeng, Amanda T., Robinson, Sophie A., Gunther, Erik C., van Dyck, Christopher H., Nygaard, Haakon B., Strittmatter, Stephen M.·2015·Annals of Neurology

DOI 10.1002/ana.24394PMC PMC4447598

Open this paper in CoChat — free account

Abstract

Objective: Currently no effective disease‐modifying agents exist for the treatment of Alzheimer disease (AD). The Fyn tyrosine kinase is implicated in AD pathology triggered by amyloid‐ß oligomers (Aßo) and propagated by Tau. Thus, Fyn inhibition may prevent or delay disease progression. Here, we sought to repurpose the Src family kinase inhibitor oncology compound, AZD0530, for AD. Methods: The pharmacokinetics and distribution of AZD0530 were evaluated in mice. Inhibition of Aßo signaling to Fyn, Pyk2, and Glu receptors by AZD0530 was tested by brain slice assays. After AZD0530 or vehicle treatment of wild‐type and AD transgenic mice, memory was assessed by Morris water maze and novel object recognition. For these cohorts, amyloid precursor protein (APP) metabolism, synaptic markers (SV2 and PSD‐95), and targets of Fyn (Pyk2 and Tau) were studied by immunohistochemistry and by immunoblotting. Results: AZD0530 potently inhibits Fyn and prevents both Aßo‐induced Fyn signaling and downstream phosphorylation of the AD risk gene product Pyk2, and of NR2B Glu receptors in brain slices. After 4 weeks of treatment, AZD0530 dosing of APP/PS1 transgenic mice fully rescues spatial memory deficits and synaptic depletion, without altering APP or Aß metabolism. AZD0530 treatment also reduces microglial activation in APP/PS1 mice, and rescues Tau phosphorylation and deposition abnormalities in APP/PS1/Tau transgenic mice. There is no evidence of AZD0530 chronic toxicity. Interpretation: Targeting Fyn can reverse memory deficits found in AD mouse models, and rescue synapse density loss characteristic of the disease. Thus, AZD0530 is a promising candidate to test as a potential therapy for AD. Ann Neurol 2015;77:953–971

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/ana.24394

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

2 retracted

RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
Retracted
RETRACTED: The Complex PrPc-Fyn Couples Human Oligomeric Aβ with Pathological Tau Changes in Alzheimer's Disease
Larson, M. E., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D. A., Aguzzi, A., & Lesné, S. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1858-12.2012 · Cited by 290
Retracted
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506

Flagged first, then by citations

Show all 62 references

1 of the 62 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 317

Proteolytic shedding of the prion protein via activation of metallopeptidase ADAM10 reduces cellular binding and toxicity of amyloid-β oligomers
Jarosz-Griffiths, H., Corbett, N. J., Rowland, H. A., Fisher, K., Jones, A. C., Baron, J., Howell, G. J., Cowley, S. A., Chintawar, S., Cader, M. Z., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005364 · Cited by 45
Fyn-tau Ablation Modifies PTZ-Induced Seizures and Post-seizure Hallmarks of Early Epileptogenesis
Putra, M. R. E., Puttachary, S., Liu, G., Lee, G. S., & Thippeswamy, T. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.592374 · Cited by 48
Fyn Kinase Activity and Its Role in Neurodegenerative Disease Pathology: a Potential Universal Target?
Guglietti, B., Sivasankar, S., Mustafa, S., Corrigan, F., & Collins‐Praino, L. E. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02518-3 · Cited by 48
Targeting dementias through cancer kinases inhibition
Fagiani, F., Lanni, C., Racchi, M., & Govoni, S. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12044 · Cited by 43
A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants
Trombetta, R. P., Dunman, P. M., Schwarz, E. M., Kates, S. L., & Awad, H. A. (2018) · mSphere · doi:10.1128/msphere.00422-18 · Cited by 43
Emerging treatments for Alzheimer’s disease for non-amyloid and non-tau targets
Khan, A., Corbett, A., & Ballard, C. G. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1326818 · Cited by 42
Developmental NMDA receptor dysregulation in the infantile neuronal ceroid lipofuscinosis mouse model
Koster, K. P., Francesconi, W., Berton, F., Alahmadi, S., Srinivas, R., & Yoshii, A. (2019) · eLife · doi:10.7554/elife.40316 · Cited by 41
Isoform‐specific upregulation of FynT kinase expression is associated with tauopathy and glial activation in Alzheimer's disease and Lewy body dementias
Low, C. Y. B., Lee, J. H., Lim, F. T. W., Lee, C., Ballard, C. G., Francis, P. T., Lai, M. K. P., & Tan, M. G. K. (2020) · Brain Pathology · doi:10.1111/bpa.12917 · Cited by 43
How to awaken your nanomachines: Site-specific activation of focal adhesion kinases through ligand interactions
Walkiewicz, K. W., Girault, J., & Arold, S. T. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.06.001 · Cited by 43
Brain penetrant kinase inhibitors: Learning from kinase neuroscience discovery
Shi, Y., & Mader, M. M. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.007 · Cited by 42
Challenges and Benefits of Repurposing Products for Use during a Radiation Public Health Emergency: Lessons Learned from Biological Threats and other Disease Treatments
DiCarlo, A. L., Cassatt, D. R., Dowling, W. E., Esker, J. I., Hewitt, J. A., Selivanova, O., Williams, M. S., & Price, P. W. (2018) · Radiation Research · doi:10.1667/rr15137.1 · Cited by 41
Citalopram restores short-term memory deficit and non-cognitive behaviors in APP/PS1 mice while halting the advance of Alzheimer's disease-like pathology
Zhang, Q., Yang, C., Liu, T., Liu, L., Li, F., Cai, Y., Lv, K., Li, X., Gao, J., Sun, D., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.021 · Cited by 40
A c-Src Inhibitor Peptide Based on Connexin43 Exerts Neuroprotective Effects through the Inhibition of Glial Hemichannel Activity
Gangoso, E., Talaverón, R., Jaraíz-Rodríguez, M., Domínguez-Prieto, M., Ezan, P., Koulakoff, A., Medina, J. M., Giaume, C., & Tabernero, A. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00418 · Cited by 38
LC-MS/MS reveals the formation of reactive ortho -quinone and iminium intermediates in saracatinib metabolism: Phase I metabolic profiling
Attwa, M. W., Kadi, A. A., Darwish, H. W., & Alrabiah, H. K. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.03.037 · Cited by 37
Fyn Tyrosine Kinase Elicits Amyloid Precursor Protein Tyr682 Phosphorylation in Neurons from Alzheimer’s Disease Patients
Iannuzzi, F., Sirabella, R., Canu, N., Maier, T. J., Annunziato, L., & Matrone, C. (2020) · Cells · doi:10.3390/cells9081807 · Cited by 37
Prion neurotoxicity
Le, N. T. T., Wu, B., & Harris, D. A. (2018) · Brain Pathology · doi:10.1111/bpa.12694 · Cited by 36
Prions and Neurodegenerative Diseases: A Focus on Alzheimer’s Disease
Crestini, A., Santilli, F., Martellucci, S., Carbone, E., Sorice, M., Piscopo, P., & Mattei, V. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215171 · Cited by 35
Dopamine agonists rescue Aβ–induced LTP impairment by Src-family tyrosine kinases
Yuanxiang, P., Janc, O. A., Grochowska, K. M., Kreutz, M. R., & Reymann, K. G. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.01.008 · Cited by 35
Panaxadiol inhibits synaptic dysfunction in Alzheimer's disease and targets the Fyn protein in APP/PS1 mice and APP-SH-SY5Y cells
Liang, X., Yao, Y., Lin, Y., Kong, L., Xiao, H., Shi, Y., & Yang, J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.02.012 · Cited by 35
Self-citation
Imaging Mechanisms of Disease Progression in Multiple Sclerosis: Beyond Brain Atrophy
Bagnato, F. R., Gauthier, S. A., Laule, C., Moore, G. R. W., Bove, R. M., Cai, Z., Cohen‐Adad, J., Harrison, D. M., Klawiter, E. C., Morrow, S. A., et al. (2020) · Journal of Neuroimaging · doi:10.1111/jon.12700 · Cited by 37
Rescue of Transgenic Alzheimer’s Pathophysiology by Polymeric Cellular Prion Protein Antagonists
Gunther, E. C., Smith, L. M., Kostylev, M. A., Cox, T. O., Kaufman, A. C., Lee, S., Folta‐Stogniew, E. J., Maynard, G. D., Um, J. W., Stagi, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.021 · Cited by 34
Self-citation
Stem Cells as Potential Targets of Polyphenols in Multiple Sclerosis and Alzheimer’s Disease
Tandon, A., Singh, S. J., & Chaturvedi, R. K. (2018) · BioMed Research International · doi:10.1155/2018/1483791 · Cited by 36
Pivotal Role of Fyn Kinase in Parkinson’s Disease and Levodopa-Induced Dyskinesia: a Novel Therapeutic Target?
Angelopoulou, E., Paudel, Y. N., Julian, T. H., Shaikh, M. F., & Piperi, C. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02201-z · Cited by 34
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy
Brody, A. H., Nies, S. H., Guan, F., Smith, L. M., Mukherjee, B., Salazar, S. A., Lee, S., Lam, T. K. T., & Strittmatter, S. M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00526-y · Cited by 36
Self-citation
Intracellular and extracellular microtubule associated protein tau as a therapeutic target in Alzheimer disease and other tauopathies
Ávila, J., Pallas‐Bazarra, N., Bolós, M., Sayas, C. L., & Hernández, F. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1131269 · Cited by 36
Synaptic Disruption by Soluble Oligomers in Patients with Alzheimer’s and Parkinson’s Disease
Gutierrez, B. A., & Limón, A. (2022) · Biomedicines · doi:10.3390/biomedicines10071743 · Cited by 32
Neuronal transcriptome, tau and synapse loss in Alzheimer’s knock-in mice require prion protein
Stoner, A. J., Fu, L., Nicholson, L., Zheng, C., Toyonaga, T., Spurrier, J. M., Laird, W., Cai, Z., & Strittmatter, S. M. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01345-z · Cited by 34
Self-citation
Chromatin accessibility mapping of the striatum identifies tyrosine kinase FYN as a therapeutic target for heroin use disorder
Egervári, G., Akpoyibo, D., Rahman, T., Fullard, J. F., Callens, J. E., Landry, J. A., Ly, A., Zhou, X., Warren, N. A., Hauberg, M. E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18114-3 · Cited by 28
Aging-related modifications to G protein-coupled receptor signaling diversity
van Gastel, J., Leysen, H., Boddaert, J., Vangenechten, L., Luttrell, L. M., Martin, B., & Maudsley, S. R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107793 · Cited by 32
Kinase Signaling in Dendritic Development and Disease
Nourbakhsh, K., & Yadav, S. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.624648 · Cited by 31
Anti‐PrPC antibody rescues cognition and synapses in transgenic alzheimer mice
Cox, T. O., Gunther, E. C., Brody, A. H., Chiasseu, M. T., Stoner, A., Smith, L. M., Haas, L. T., Hammersley, J., Rees, G., Dosanjh, B., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.730 · Cited by 33
Self-citation
Family C G-Protein-Coupled Receptors in Alzheimer’s Disease and Therapeutic Implications
Prà, I. D., Armato, U., & Chiarini, A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01282 · Cited by 31
Common variant in PTK2B is associated with late-onset Alzheimer’s disease: A replication study and meta-analyses
Li, Y., Tan, M., Wang, H.-F., Tan, C., Zhang, W., Zheng, Z.-J., Kong, L., Wang, Z.-X., Tan, L., Jiang, T., et al. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.04.020 · Cited by 32
MTSS1/Src family kinase dysregulation underlies multiple inherited ataxias
Brown, A. S., Meera, P., Altindag, B., Chopra, R., Perkins, E., Paul, S., Scoles, D., Tarapore, E., Magri, J., Huang, H.-R., et al. (2018) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1816177115 · Cited by 28
Microorganisms Associated with the Marine Sponge Scopalina hapalia: A Reservoir of Bioactive Molecules to Slow Down the Aging Process
Hassane, C. S., Fouillaud, M., Goff, G. L., Sklirou, A. D., Boyer, J. B., Trougakos, I. P., Jerabek, M., Bignon, J. S., de Voogd, N. J., Ouazzani, J., et al. (2020) · Microorganisms · doi:10.3390/microorganisms8091262 · Cited by 33
Long‐term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease
Alldred, M. J., Chao, H. M., Lee, S. H., Beilin, J., Powers, B. E., Petkova, E., Strupp, B. J., & Ginsberg, S. D. (2019) · The FASEB Journal · doi:10.1096/fj.201802669rr · Cited by 29
A key requirement for synaptic Reelin signaling in ketamine-mediated behavioral and synaptic action
Kim, J., Herz, J., Kavalali, E. T., & Monteggia, L. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103079118 · Cited by 29
Masitinib for the Treatment of Alzheimer’s Disease
Ettcheto, M., Cano, A., Sanchez-López, E., Verdaguer, E., Folch, J., Auladell, C., & Camins, A. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0019 · Cited by 28
In vivo imaging of synaptic density in neurodegenerative disorders with positron emission tomography: A systematic review
Visser, M., O’Brien, J. T., & Mak, E. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102197 · Cited by 28
A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease
van Dyck, C. H., Mecca, A. P., O’Dell, R. S., Bartlett, H. H., Diepenbrock, N. G., Huang, Y., Hamby, M. E., Grundman, M., Catalano, S. M., Caggiano, A. O., et al. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01382-2 · Cited by 29
Early Activation of Experience-Independent Dendritic Spine Turnover in a Mouse Model of Alzheimer's Disease
Heiss, J. K., Barrett, J., Yu, Z., Haas, L. T., Kostylev, M. A., & Strittmatter, S. M. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhw188 · Cited by 30
Self-citation
Saracatinib, a Src Tyrosine Kinase Inhibitor, as a Disease Modifier in the Rat DFP Model: Sex Differences, Neurobehavior, Gliosis, Neurodegeneration, and Nitro-Oxidative Stress
Gage, M., Putra, M. R. E., Wachter, L., Dishman, K., Gard, M., Gomez-Estrada, C., & Thippeswamy, T. (2021) · Antioxidants · doi:10.3390/antiox11010061 · Cited by 28
Pyk2 overexpression in postsynaptic neurons blocks amyloid β1–42-induced synaptotoxicity in microfluidic co-cultures
Kilinc, D., Vreulx, A.-C., Mendes, T., Flaig, A., Coelho, D. M., Verschoore, M., Demiautte, F., Amouyel, P., Bank, N.-C. B., Eysert, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa139 · Cited by 34
Src family kinases activity is required for transmitting purinergic P2X7 receptor signaling in cortical spreading depression and neuroinflammation
Nie, L., Ma, D., Quinn, J. P., & Wang, M. (2021) · The Journal of Headache and Pain · doi:10.1186/s10194-021-01359-8 · Cited by 27
PET Imaging in Animal Models of Alzheimer’s Disease
Chen, B., Marquez-Nostra, B. V., Belitzky, E., Toyonaga, T., Tong, J., Huang, Y. H., & Cai, Z. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.872509 · Cited by 27
Selective induction of alternatively spliced FynT isoform by TNF facilitates persistent inflammatory responses in astrocytes
Lee, C., Low, C. Y. B., Wong, S. Y., Lai, M. K. P., & Tan, M. G. K. (2017) · Scientific Reports · doi:10.1038/srep43651 · Cited by 27
Fyn depletion ameliorates tauP301L-induced neuropathology
Liu, G., Fiock, K. L., Levites, Y., Golde, T. E., Hefti, M. M., & Lee, G. S. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00979-6 · Cited by 32
Therapeutic modulation of neurogenesis to improve hippocampal plasticity and cognition in aging and Alzheimer's disease
MOSTAFA, M., Disouky, A., & Lazarov, O. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00580 · Cited by 31
Chinese Herbal Medicine Xueshuantong Enhances Cerebral Blood Flow and Improves Neural Functions in Alzheimer’s Disease Mice
Huang, Y., Guo, B., Shi, B., Gao, Q., & Zhou, Q. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170763 · Cited by 26
Modified Glutamatergic Postsynapse in Neurodegenerative Disorders
Moraes, B. J., Coelho, P., Fão, L., Ferreira, I. L., & Rego, A. C. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.12.002 · Cited by 27
Spatial Training Ameliorates Long-Term Alzheimer's Disease-Like Pathological Deficits by Reducing NLRP3 Inflammasomes in PR5 Mice
Ren, Q., Gong, W.-G., Zhou, H., Shu, H., Wang, Y., & Zhang, Z. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-00698-w · Cited by 26
Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice
Carter, A. Y., Letronne, F., Fitz, N. F., Mounier, A., Wolfe, C. M., Nam, K. N., Reeves, V. L., Kamboh, H., Lefterov, I., & Koldamova, R. (2017) · PLOS ONE · doi:10.1371/journal.pone.0172161 · Cited by 28
Menadione sodium bisulfite inhibits the toxic aggregation of amyloid-β(1–42)
Zhang, Y., Zhao, Y., Wang, Z., Gong, H., Ma, L., Sun, D., Yang, C., Li, Y., Cheng, B., Petersen, R. B., et al. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.07.019 · Cited by 26
Dual Drug Repurposing: The Example of Saracatinib
Ramos, R., & Vale, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084565 · Cited by 24
The Kinase Fyn As a Novel Intermediate in l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Sanz‐Blasco, S., Bordone, M., Damianich, A., Gómez, G., Bernardi, A., Isaja, L., Taravini, I. R. E., Hanger, D. P., Avale, M. E., Gershanik, O. S., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0748-3 · Cited by 24
The Y682ENPTY687 motif of APP: Progress and insights toward a targeted therapy for Alzheimer’s disease patients
Matrone, C., Iannuzzi, F., & Annunziato, L. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.04.003 · Cited by 24
Differential Impact of Severity and Duration of Status Epilepticus, Medical Countermeasures, and a Disease-Modifier, Saracatinib, on Brain Regions in the Rat Diisopropylfluorophosphate Model
Gage, M., Putra, M. R. E., Gomez-Estrada, C., Golden, M., Wachter, L., Gard, M., & Thippeswamy, T. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.772868 · Cited by 23
Src inhibition attenuates polyglutamine-mediated neuromuscular degeneration in spinal and bulbar muscular atrophy
Iida, M., Sahashi, K., Kondo, N., Nakatsuji, H., Tohnai, G., Tsutsumi, Y., Noda, S., Murakami, A., Onodera, K., Okada, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12282-7 · Cited by 22
Spreading of Alzheimer tau seeds is enhanced by aging and template matching with limited impact of amyloid-β
Nies, S. H., Takahashi, H., Herber, C. S., Huttner, A. J., Chase, A., & Strittmatter, S. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101159 · Cited by 25
Self-citation
Standing on the shoulders of giants: a retrospective analysis of kinase drug discovery at AstraZeneca
Kettle, J. G., & Wilson, D. M. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.007 · Cited by 22
Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease
Ruthirakuhan, M. T., Herrmann, N., Suridjan, I., Abraham, E. H., Farber, I., & Lanctôt, K. L. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1258060 · Cited by 21
Loss of tau and Fyn reduces compensatory effects of MAP2 for tau and reveals a Fyn‐independent effect of tau on calcium
Liu, G., Thangavel, R., Rysted, J., Kim, Y., Francis, M. B., Adams, E., Lin, Z., Taugher, R. J., Wemmie, J. A., Usachev, Y. M., et al. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24517 · Cited by 22
Interaction of Tau, IL-6 and mitochondria on synapse and cognition following sevoflurane anesthesia in young mice
Zhang, J., Dong, Y., Huang, L., Xu, X., Liang, F., Soriano, S. G., Zhang, Y., & Xie, Z. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2020.100133 · Cited by 23
The protein-tyrosine phosphatase DEP-1 promotes migration and phagocytic activity of microglial cells in part through negative regulation of fyn tyrosine kinase
Schneble, N., Müller, J., Kliche, S., Bauer, R., Wetzker, R., Böhmer, F., Wang, Z., & Müller, J. P. (2016) · Glia · doi:10.1002/glia.23100 · Cited by 22
Advancements of the sFIDA method for oligomer‐based diagnostics of neurodegenerative diseases
Kulawik, A., Heise, H., Zafiu, C., Willbold, D., & Bannach, O. (2018) · FEBS Letters · doi:10.1002/1873-3468.12983 · Cited by 21
Protective role of anticancer drugs in neurodegenerative disorders: A drug repurposing approach
Advani, D., Gupta, R. V., Tripathi, R. S., Sharma, S., Ambasta, R. K., & Kumar, P. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104841 · Cited by 24
Fyn nanoclustering requires switching to an open conformation and is enhanced by FTLD-Tau biomolecular condensates
Martínez‐Mármol, R., Small, C., Jiang, A., Palliyaguru, T., Wallis, T. P., Gormal, R. S., Sibarita, J., Götz, J., & Meunier, F. A. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01825-y · Cited by 21
Regulation of beta‐amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds
Qiu, W., Liu, H., Liu, Y., Lü, X., Wang, L., Hu, Y., Feng, F., Li, Q., & Sun, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21947 · Cited by 20
Glucosylpolyphenols as Inhibitors of Aβ-Induced Fyn Kinase Activation and Tau Phosphorylation: Synthesis, Membrane Permeability, and Exploratory Target Assessment within the Scope of Type 2 Diabetes and Alzheimer’s Disease
de Matos, A. M., Blázquez‐Sánchez, M. T., Bento‐Oliveira, A., de Almeida, R. F. M., Nunes, R. S., Lopes, P. E. M., Machuqueiro, M., Cristóvão, J. S., Gomes, C. M., Souza, C. D. S., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00841 · Cited by 22
Role of Fyn Kinase Inhibitors in Switching Neuroinflammatory Pathways
Marotta, G., Basagni, F., Rosini, M., & Minarini, A. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867329666211221153719 · Cited by 21
Lipid Rafts Act as a Common Platform for Amyloid-β Oligomer-Induced Alzheimer’s Disease Pathology
Kawarabayashi, T., Nakamura, T., Sato, K., Seino, Y., Ichii, S., Nakahata, N., Takatama, M., Westaway, D. A., George‐Hyslop, P. S., & Shoji, M. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215662 · Cited by 22
Loss of miR-369 Promotes Tau Phosphorylation by Targeting the Fyn and Serine/Threonine-Protein Kinase 2 Signaling Pathways in Alzheimer’s Disease Mice
Yao, X., Xian, X., Fang, M., Fan, S., & Li, W. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00365 · Cited by 21
Targeted Downregulation of dMyc Suppresses Pathogenesis of Human Neuronal Tauopathies in Drosophila by Limiting Heterochromatin Relaxation and Tau Hyperphosphorylation
Chanu, S. I., & Sarkar, S. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9858-6 · Cited by 20
Shared pathological pathways of Alzheimer's disease with specific comorbidities: current perspectives and interventions
Nday, C. M., Eleftheriadou, D., & Jackson, G. E. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14256 · Cited by 21
A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-beta Oligomers
Silverman, J. M., Gibbs, E., Peng, X., Martens, K. M., Balducci, C., Wang, J., Yousefi, M., Cowan, C. M., Lamour, G., Louadi, S., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00469 · Cited by 21
The Radiosensitizing Effect of AZD0530 in Glioblastoma and Glioblastoma Stem-Like Cells
Yun, H. S., Lee, J., Kil, W. J., Kramp, T. R., Tofilon, P. J., & Camphausen, K. A. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0883 · Cited by 19
The next step of neurogenesis in the context of Alzheimer’s disease
Moradi, H. R., Hajali, V., Khaksar, Z., Vafaee, F., Forouzanfar, F., & Negah, S. S. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06520-9 · Cited by 20
Vascular and non‐vascular contributors to memory reduction during traumatic brain injury
Charkviani, M., Muradashvili, N., & Lominadze, D. G. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14390 · Cited by 17
Vascular Effects on Cerebrovascular Permeability and Neurodegeneration
Sulimai, N., Brown, J. D., & Lominadze, D. G. (2023) · Biomolecules · doi:10.3390/biom13040648 · Cited by 17
Enhanced Fyn-tau and NR2B-PSD95 interactions in epileptic foci in experimental models and human epilepsy
Putra, M. R. E., Rao, N. S., Gardner, C., Liu, G., Trommater, J., Bunney, M., Gage, M., Bassuk, A. G., Hefti, M. M., Lee, G. S., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae327 · Cited by 17
cAMP-Fyn signaling in the dorsomedial striatum direct pathway drives excessive alcohol use
Ehinger, Y., Morisot, N., Phamluong, K., Sakhai, S. A., Soneja, D., Adrover, M. F., Alvarez, V. A., & Dorit Ron, A. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0712-1 · Cited by 17
Src Family Kinases Facilitate the Crosstalk between CGRP and Cytokines in Sensitizing Trigeminal Ganglion via Transmitting CGRP Receptor/PKA Pathway
Nie, L., Sun, K., Gong, Z., Li, H., Quinn, J. P., & Wang, M. (2022) · Cells · doi:10.3390/cells11213498 · Cited by 16
Microglia PTK2B/Pyk2 in the Pathogenesis of Alzheimer’s Disease
Guo, Y., Sun, C.-K., Tang, L., & Tan, M. (2023) · Current Alzheimer Research · doi:10.2174/0115672050299004240129051655 · Cited by 17
The Fyn kinase inhibitor, AZD0530 , suppresses mouse alcohol self‐administration and seeking
Morisot, N., Berger, A. L., Phamluong, K., Cross, A. J., & Dorit Ron, A. (2018) · Addiction Biology · doi:10.1111/adb.12699 · Cited by 15
PET Imaging of Synaptic Vesicle Protein 2A
Finnema, S. J., Li, S., Cai, Z., Naganawa, M., Chen, M.-K., Matuskey, D., Nabulsi, N., Esterlis, I., Holmes, S. E., Radhakrishnan, R., et al. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_29 · Cited by 17
Antineoplastics for treating Alzheimer's disease and dementia: Evidence from preclinical and observational studies
Das, V., Miller, J. H., Goud, A. C., Annadurai, N., Sanctis, J. B. D., Hrubá, L., & Hajdúch, M. (2024) · Medicinal Research Reviews · doi:10.1002/med.22033 · Cited by 16
Preventing the Spread of Alzheimer’s Disease Neuropathology: A Role for Calcilytics?
Chiarini, A., Gardenal, E., Whitfield, J., Chakravarthy, B., Armato, U., & Prà, I. D. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201016666150505123813 · Cited by 14
Therapeutic strategies for tauopathies and drug repurposing as a potential approach
Islam, M., Shen, F., Regmi, D., & Du, D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114979 · Cited by 14
Integrated Analysis of Competitive Endogenous RNA Networks in Acute Ischemic Stroke
Wu, Z., Wei, W., Fan, H., Gu, Y., Li, L., & Wang, H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.833545 · Cited by 14
A systematic review on drugs for synaptic plasticity in the treatment of dementia
Piscopo, P., Crestini, A., Carbone, E., Rivabene, R., Ancidoni, A., Giudice, M. L., Corbo, M., Vanacore, N., & Lacorte, E. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101726 · Cited by 16
A Systematic Bioinformatics Workflow With Meta-Analytics Identified Potential Pathogenic Factors of Alzheimer’s Disease
Yuen, S. C., Zhu, H., & Leung, S.-W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00209 · Cited by 16
Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression
Asch, R. H., Abdallah, C. G., Carson, R. E., & Esterlis, I. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01913-3 · Cited by 13
A 3D human iPSC-derived multi-cell type neurosphere system to model cellular responses to chronic amyloidosis
Wendt, S., Lin, A. J., Ebert, S. N., Brennan, D. J., Cai, W., Bai, Y., Kong, D. Y., Sorrentino, S., Groten, C. J., Lee, C., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03433-3 · Cited by 13
Self-citation
Research Progress on the Etiology and Pathogenesis of Alzheimer's Disease from the Perspective of Chronic Stress
Liu, Y., Zhao, H., Li, Q., Cui, H.-W., & Huang, G. (2022) · Aging and Disease · doi:10.14336/ad.2022.1211 · Cited by 15
Post-status epilepticus treatment with the Fyn inhibitor, saracatinib, improves cognitive function in mice
Luo, X., Zhao, J., Wu, W., Fu, J., Li, Z., Zhang, M., & Lu, J. (2021) · BMC Neuroscience · doi:10.1186/s12868-020-00606-z · Cited by 13
Heat shock protein amplification improves cerebellar myelination in the Npc1nih mouse model
Gray, J., Fernández‐Suárez, M. E., Falah, M. M., Smith, D. A., Smith, C., Kaya, E., Palmer, A. M., Fog, C. K., Kirkegaard, T., & Platt, F. M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104374 · Cited by 14
Compound asset sharing initiatives between pharmaceutical companies, funding bodies, and academia: Learnings and successes
Hayes, A. G., & Nutt, D. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.510 · Cited by 13
Tyrosine kinases: multifaceted receptors at the intersection of several neurodegenerative disease-associated processes
Stevenson, M. E., Algarzae, N. K., & Moussa, C. (2024) · Frontiers in Dementia · doi:10.3389/frdem.2024.1458038 · Cited by 13
Molecular Insights into Tau Pathology and its Therapeutic Strategies in Alzheimer's Disease
Zhou, F., Zhao, Y., Sun, Y., & Chen, W. (2024) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2311197 · Cited by 13
Gene-environment interaction promotes Alzheimer's risk as revealed by synergy of repeated mild traumatic brain injury and mouse App knock-in
Chiasseu, M., Fesharaki‐Zadeh, A., Saito, T., Saido, T. C., & Strittmatter, S. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105059 · Cited by 11
Self-citation

Authors: Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., van Dyck, C. H., Nygaard, H. B., & Strittmatter, S. M.
Affiliations: Yale University (US)
Department of Psychiatry Yale University School of Medicine New Haven CT
Corresponding author: Strittmatter, Stephen M.
ORCID: Kaufman, Adam C.
Salazar, Santiago V.
Yang, Jinhee
Kostylev, Mikhail A.
Robinson, Sophie A.
Nygaard, Haakon B.
Strittmatter, Stephen M.
Venue: Annals of Neurology
Publisher: Wiley
Published: 2015-03-21
Volume: 77
Issue: 6
Pages: 953-971
ISSN: 0364-5134 (ISSN-L)
1531-8249
DOI: 10.1002/ana.24394
PMC: PMC4447598
OpenAlex: W1725757145
Cited by: 314
References: 62
Citations by year: 2026: 16 · 2025: 13 · 2024: 19 · 2023: 25 · 2022: 28 · 2021: 38 · 2020: 41 · 2019: 28 · 2018: 40 · 2017: 29 · 2016: 24 · 2015: 13
FWCI: 25.77
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Annals of Neurology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (UH3-TR000967, R01AG034924)
BrightFocus Foundation
Alzheimer's Association
Falk Medical Research Trust
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: Alzheimer's disease, Fyn tyrosine kinase, AZD0530, Src family kinase inhibitor, amyloid-beta oligomers, Pyk2, NMDA receptor NR2B, APP/PS1 mice, spatial memory impairment, synaptic loss, PSD-95, microglial activation, tau phosphorylation, drug repurposing, disease-modifying therapy
MeSH terms: Alzheimer Disease, Animals, Behavior, Animal, Disease Models, Animal, Mice, Inbred C57BL, Mice, Transgenic, Quinazolines, Signal Transduction, Amyloid beta-Peptides, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-fyn, Mice, Focal Adhesion Kinase 2, Benzodioxoles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fyn inhibition rescues established memory and synapse loss in Alzheimer mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks